EUROPA PASA DE TENER DOS TRATAMIENTOS SCLC-ES EN PRIMERA LINEA INMUNOTERAPIA ( ATEZOLIZUMAB
Y DURVALUMAB ) ... A TENER CUATRO ( ATEZOLIZUMAB, DURVALUMAB , SERPLULIMAB Y TISLELIZUMAB ) .
I'm a stage 4 synovial cell survivor and I live in Northern California. I have been in the ET-743 ( Yondelis ) study since Sept. 2005. For me it has been my miracle drug.